Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500551 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
A Phase 2 study of Juvenile Idiopathic Arthritis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
- 20
- Study locations
NCT01500551: Completed Phase 2 study of Juvenile Idiopathic Arthritis, sponsored by Pfizer.
NCT01500551 is a Phase 2 study of Juvenile Idiopathic Arthritis that has completed, run by Pfizer. The registered enrollment target is 302 participants, above the 265-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01500551, a Phase 2 study of Juvenile Idiopathic Arthritis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
Primary Outcome
Parameters: Hematology (hemoglobin, hematocrit, erythrocytes, platelets, leukocytes, lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes, prothrombin international normalized ratio, erythrocyte sedimentation rate), clinical chemistry (bilirubin, direct/indirect bilirubin, aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phospha
Conditions Studied
Interventions
- DRUG Tofacitinib
Study Locations (20)
California
- Loma Linda University Children'S Hospital - Loma Linda
- Loma Linda University Clinical Trials Center - Loma Linda
- Loma Linda University Eye Institute - Loma Linda
- Loma Linda University General Pediatric Clinic - Meridian - Loma Linda
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology) - Loma Linda
- Children's Hospital Los Angeles - Los Angeles
- Pediatric Speciality Team Centers of LLU Children's Hospital (Rheumatology) - San Bernardino
- Rady Children's Hospital Center for Pediatric Clinical Research - San Diego
- Rady Children's Hospital Rheumatology Clinic - San Diego
- Rady Children's Hospital San Diego- Education and Office Building - San Diego
- Rady Children's Hospital San Diego - San Diego
- Rady Children's Research Pharmacy - San Diego
Georgia
- Center for Advanced Pediatrics - Atlanta
- AU Medical Center - Augusta
- Augusta University - Augusta
District of Columbia
- Children's National Medical Center - Washington D.C.
- IDS Pharmacy - Washington D.C.
Arkansas
- Arkansas Children's Hospital - Little Rock
Connecticut
- Connecticut Children's Medical Center - Hartford
Florida
- Nicklaus Children's Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2013-03-18 |
| Est. Completion | 2025-02-12 |
| Phase | Phase 2 |
What the finished NCT01500551 record still lists
NCT01500551 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, above the 265-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Juvenile Idiopathic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Tofacitinib is the first listed.
NCT01500551 names 20 study sites across 6 states, led by California, Georgia, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01500551 about?
NCT01500551 is a clinical study titled "Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis". Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
What is the current status of trial NCT01500551?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2013-03-18. Estimated completion is 2025-02-12.
What conditions does trial NCT01500551 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis.
What interventions are being tested in trial NCT01500551?
The interventions under investigation include: Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT01500551?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01500551 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01500551's enrollment target sits among peer trials
302 3rd of 8 higher than 6 of 8 other Juvenile Idiopathic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Juvenile Idiopathic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
RECRUITING · Phase 3
-
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
RECRUITING
-
Pain in Juvenile Arthritis
RECRUITING · NA
-
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
ACTIVE NOT RECRUITING
-
Juvenile Idiopathic Arthritis (JIA) Registry
COMPLETED
-
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI